Insights

Asset Disposition The company recently sold assets and IP to Invero Pharma, indicating potential strategic shifts or opportunities for partners to engage in post-transaction collaboration, licensing, or acquisition discussions related to the xenon-based neuroprotection platform.

Clinical Progress NeuroproteXeon is preparing for a Phase III trial in Out of Hospital Cardiac Arrest, signaling ongoing late-stage development and a need for trial support, contract research, and scalable manufacturing or inhalation device optimization partners.

Funding Profile Reported revenue in the low to mid single-digit millions suggests a compact budget environment; opportunities exist to offer cost-effective CROs, GMP manufacturing, regulatory affairs support, and partnerships that maximize ROI for late-stage clinical programs.

Technology Stack Reliance on standard SaaS and web technologies implies potential for associated IT services, cloud hosting, cybersecurity, and data analytics vendors to support clinical data management, patient engagement platforms, and website/infrastructure needs.

Market Positioning As a niche neuroprotection player with a xenon-based approach, there is potential to position with larger pharma companies for out-licensing, co-development, or strategic alliances focused on acute brain injury indications and hospital-based deployment.

Similar companies to NeuroproteXeon

NeuroproteXeon Tech Stack

NeuroproteXeon uses 8 technology products and services including Cloudflare, WordPress, MySQL, and more. Explore NeuroproteXeon's tech stack below.

  • Cloudflare
    Content Management System
  • Content Management System
  • MySQL
    Database
  • Font Awesome
    Font Scripts
  • Google Fonts API
    Font Scripts
  • jQuery Migrate
    Javascript Libraries
  • Slider Revolution
    Miscellaneous
  • GoDaddy
    Web Hosting

NeuroproteXeon's Email Address Formats

NeuroproteXeon uses at least 1 email format:
NeuroproteXeon Email FormatsExamplePercentage
FirstLast@neuroprotexeon.comJohnDoe@neuroprotexeon.com
100%

Frequently Asked Questions

What is NeuroproteXeon's phone number?

Minus sign iconPlus sign icon
You can contact NeuroproteXeon's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is NeuroproteXeon's official website and social media links?

Minus sign iconPlus sign icon
NeuroproteXeon's official website is neuroprotexeon.com and has social profiles on LinkedIn.

How much revenue does NeuroproteXeon generate?

Minus sign iconPlus sign icon
As of November 2026, NeuroproteXeon's annual revenue is estimated to be $1M - $10M.

What is NeuroproteXeon's NAICS code?

Minus sign iconPlus sign icon
NeuroproteXeon's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does NeuroproteXeon have currently?

Minus sign iconPlus sign icon
As of November 2026, NeuroproteXeon has approximately 3 employees across 1 continents, including North America. Key team members include Chief Executive Officer: B. B., Document Controller: J. B. and Document Controller: D. B. Explore NeuroproteXeon's employee directory with LeadIQ.

What industry does NeuroproteXeon belong to?

Minus sign iconPlus sign icon
NeuroproteXeon operates in the Pharmaceutical Manufacturing industry.

What technology does NeuroproteXeon use?

Minus sign iconPlus sign icon
NeuroproteXeon's tech stack includes Cloudflare, WordPress, MySQL, Font Awesome, Google Fonts API, jQuery Migrate, Slider Revolution and GoDaddy.

What is NeuroproteXeon's email format?

Minus sign iconPlus sign icon
NeuroproteXeon's email format typically follows the pattern of FirstLast@neuroprotexeon.com. Find more NeuroproteXeon email formats with LeadIQ.

When was NeuroproteXeon founded?

Minus sign iconPlus sign icon
NeuroproteXeon was founded in 2015.
NeuroproteXeon logo

NeuroproteXeon

Pharmaceutical ManufacturingNew York, United States2-10 Employees

NeuroproteXeon is a late clinical-stage pharmaceutical company focused on preventing brain cell death after acute neurological injury by using xenon gas administered through a specialized inhalation device. The approach targets protection of brain tissue in patients experiencing events such as out-of-hospital cardiac arrest, and the company is preparing for a Phase III trial in that indication. Headquartered in Orchard Park, New York, the organization operates with a small team within the pharmaceutical manufacturing sector. In 2021, the company disclosed the sale of its assets and intellectual property to Invero Pharma LLC.

Section iconCompany Overview

Phone number
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2015
Employees
2-10

Section iconFunding & Financials

  • $1M - $10M

    NeuroproteXeon's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.